Cigna

Cigna (CI) Q2 2026 Earnings

Reported Jul 30, 2026 at 6:16 AM ET · SEC Source

Q2 26 EPS

$7.78

Q2 26 Revenue

$71.67B

vs S&P Since Q2 26

-8.8%

TRAILING MARKET

CI -4.6% vs S&P +4.3%

Market Reaction

Did CI Beat Earnings? Q2 2026 Results

The Cigna Group delivered a stronger-than-expected second quarter, posting adjusted EPS of $7.78 and total revenues of $71.67 billion, beating analyst consensus estimates of $7.59 and $70.18 billion, respectively, extending the company's streak of to… Read more The Cigna Group delivered a stronger-than-expected second quarter, posting adjusted EPS of $7.78 and total revenues of $71.67 billion, beating analyst consensus estimates of $7.59 and $70.18 billion, respectively, extending the company's streak of topping consensus EPS expectations to five consecutive quarters. The headline driver was a standout performance from Cigna Healthcare, where adjusted pre-tax income climbed 17% year-over-year to $1.28 billion on the back of improved margins in the U.S. Employer business, helping offset a 27% decline in Pharmacy Benefit Services pre-tax income tied to large client contract renewals that management had previously flagged. Evernorth's Specialty and Care Services unit also contributed meaningfully, with adjusted pre-tax income rising 22% to $1.05 billion, fueled by specialty volume growth and broader biosimilar adoption. Reflecting the quarter's momentum and its ongoing pivot toward employer-sponsored healthcare and pharmacy benefits management, Cigna raised its full-year 2026 adjusted EPS outlook by $0.10 to at least $30.45 per share, nudging above the prior analyst consensus.

Key Takeaways

  • Growth in both Evernorth Health Services and Cigna Healthcare drove 7% total revenue increase
  • Cigna Healthcare adjusted income from operations increased 17% driven by improved U.S. Employer business margins
  • Specialty and Care Services adjusted income grew 22% from strong organic growth, higher generic and biosimilar adoption, and operating efficiencies
  • Operating efficiency improved with adjusted SG&A expense ratio declining to 4.6% from 4.9%
  • Premium rate increases to cover expected increases in medical costs drove Cigna Healthcare revenue growth

CI Forward Guidance & Outlook

The Cigna Group raised its full-year 2026 outlook for consolidated adjusted income from operations to at least $30.45 per share, an increase of $0.10 from the prior projection. Segment-level guidance includes: Evernorth adjusted income from operations, pre-tax, of at least $6,900 million (unchanged); Cigna Healthcare adjusted income from operations, pre-tax, of at least $4,550 million (up $25 million). The Cigna Healthcare medical care ratio is projected at 83.7% to 84.7% for the full year. The outlook includes the impact of expected future share repurchases and anticipated 2026 dividends, but excludes potential effects of any business combinations after the date of this release.

24/7 Wall St

CI YoY Financials

Q2 2026 vs Q2 2025, source: SEC Filings

24/7 Wall St

CI Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q2 26

“Our purpose is to improve the lives of each and every customer and patient we serve. By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution.”

— Brian C. Evanko, Q2 2026 Earnings Press Release